<DOC>
	<DOCNO>NCT02284425</DOCNO>
	<brief_summary>This phase 1 , randomize , double-blind , placebo-controlled study evaluate safety tolerability REGN1193 patient Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>Study REGN1193 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Metformin monotherapy dose ≥1000 mg/day ( maximum daily dose 2550 mg per day ) ≥8 week prior randomization 2 . Hemoglobin A1c value ≥7.0 % ≤10.0 % 3 . Fasting plasma glucose value ≥130 mg/dL ≤240 mg/dL 1 . Type 1 diabetes mellitus 2 . Use insulin oral injectable antihyperglycemic medication 8 week prior randomization 3 . A severe hypoglycemic event 6 month prior randomization Note : The eligibility criterion list intend contain consideration relevant patient 's potential participation clinical trial therefore inclusion/ exclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>